| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD004756.PUB3 |
| P698 | PubMed publication ID | 16625610 |
| P50 | author | Angela Webster | Q37834876 |
| Jonathan Craig | Q38591193 | ||
| P2093 | author name string | Tanya Pankhurst | |
| Jeremy R Chapman | |||
| Fiona Rinaldi | |||
| P2860 | cites work | Interleukin 2 receptor antagonists for kidney transplant recipients | Q24247441 |
| What is meant by intention to treat analysis? Survey of published randomised controlled trials | Q24647858 | ||
| Reporting of adverse drug reactions in randomised controlled trials - a systematic survey | Q24805597 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection | Q28209762 | ||
| Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data | Q31004418 | ||
| Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data | Q31036557 | ||
| A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection | Q32041368 | ||
| The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group | Q32062983 | ||
| Immunosuppressive strategies in transplantation | Q33591791 | ||
| The US multicenter double-blind, randomized, phase III trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design | Q33636560 | ||
| Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy | Q34264600 | ||
| Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors | Q34389549 | ||
| The impact of late acute rejection after cadaveric kidney transplantation | Q34421534 | ||
| Identifying relevant studies for systematic reviews | Q36888457 | ||
| The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study | Q40842693 | ||
| Sensitization following Thymoglobulin and Atgam rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. US Thymoglobulin Multi-Center Study Group | Q41699742 | ||
| Impact of acute rejection therapy on infections and malignancies in renal transplant recipients | Q42480843 | ||
| Balancing benefits and harms in health care. | Q42784217 | ||
| Controversy in Counting and Attributing Events in Clinical Trials | Q44806473 | ||
| Costs savings associated with thymoglobulin for treatment of acute renal transplant rejection in patient subsets | Q46777806 | ||
| Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation | Q47784519 | ||
| Problems and Limitations in Conducting Systematic Reviews | Q56528247 | ||
| Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin | Q67271851 | ||
| Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients | Q68052458 | ||
| OKT3: First-dose safety and success | Q68183852 | ||
| A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants | Q69865410 | ||
| Treatment of acute rejection of cadaveric renal allografts with rabbit antithymocyte globulin | Q70222500 | ||
| Low-dose maintenance prednisone and antilymphoblast globulin for the treatment of acute rejection. A steroid-sparing approach to immunosuppressive therapy | Q70253903 | ||
| Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection | Q71223575 | ||
| Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study | Q73278465 | ||
| Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodes | Q73352968 | ||
| A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results | Q73544640 | ||
| Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial | Q73585321 | ||
| High risk kidney transplant rejection treatment: cost savings from thymoglobulin | Q74616023 | ||
| ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial | Q77068653 | ||
| Correlation of histology to clinical rejection reversal: a thymoglobulin multicenter trial report | Q77829490 | ||
| Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections | Q93911540 | ||
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P577 | publication date | 2006-04-19 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients |
| Q35559431 | Acute respiratory failure in kidney transplant recipients: a multicenter study |
| Q38057787 | Disruptions in the Supply of Medications Used in Transplantation: Implications and Management Strategies for the Transplant Clinician |
| Q24247263 | Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients |
| Q30239091 | Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. |
| Q38668319 | Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients |
| Q36465981 | Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a |
Search more.